Proietto J, et al. - In this multicenter randomized double-blind placebo-controlled clinical trial, researchers tested the effectiveness and safety of a methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib, in people with obesity (BMI ≥30 kg/m²) and type 2 diabetes (HbA_1c 53–97 mmol/mol [7–11%] and fasting glucose <15.6 mmol/l). For producing meaningful weight loss and improvement in HbA_1c, MetAP2 inhibitors represent a novel mechanism. Sleep related adverse events, like insomnia, abnormal dreams, and sleep disorder were the most common reasons for stopping treatment with beloranib.